Arihant Capital Markets (‘Manager to the Offer’) on behalf of Ipca Laboratories (‘Acquirer’) has informed about this Post Offer Public Announcement to the shareholders of Krebs Biochemicals and Industries (‘Target Company’), pursuant to Regulation 18 (12) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations 2011, as amended (SEBI SAST Regulations) In respect of Open Offer to acquire up to 35,73,515 Equity Shares, constituting 26% of the fully diluted voting Equity Share Capital (the ‘Offer’) of Target Company. The Detailed Public Statement (‘DPS) with respect to the aforementioned Offer was published on February 24, 2015.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: